PharmaSGP Holding SE represents values of innovation, quality, and sustainability, as reflected in their corporate philosophy. The company focuses on developing and marketing over-the-counter healthcare and pharmaceutical products. With a strong commitment to health and well-being, PharmaSGP Holding SE strives to provide effective and safe solutions for its customers. Their dedication to research and development ensures the continuous improvement and advancement of their product portfolio. By combining expertise and cutting-edge technologies, PharmaSGP Holding SE aims to contribute to the overall improvement of people's lives.

PharmaSGP Holding SE is primarily present in Germany and Austria.

PharmaSGP Holding SE, a renowned pharmaceutical company, has achieved several significant milestones throughout its successful journey. It has consistently focused on delivering innovative healthcare solutions to its customers, establishing itself as a trusted name in the industry. The company has expanded its market presence by entering into strategic partnerships and collaborations, enabling it to reach a wider customer base. Additionally, PharmaSGP Holding SE has demonstrated remarkable growth by continuously introducing new products and expanding its product portfolio. With its commitment to excellence and dedication to improving overall wellness, PharmaSGP Holding SE has emerged as a leading player in the pharmaceutical sector.

PharmaSGP Holding SE is a prominent pharmaceutical company founded in Germany. With a rich history in the healthcare sector, PharmaSGP has grown steadily over the years. The company primarily focuses on the development, production, and distribution of over-the-counter (OTC) medicines and health products. Backed by extensive research and a team of experts, PharmaSGP aims to improve the well-being of its consumers by offering effective and innovative solutions. With its commitment to quality, safety, and customer satisfaction, PharmaSGP has become a trusted name in the pharmaceutical industry. Their dedication to research and development ensures that they stay at the forefront of providing cutting-edge healthcare products and services.

The main competitors of PharmaSGP Holding SE in the market are other pharmaceutical companies operating in the same industry. Some notable competitors include major players like Bayer AG, Novartis AG, and Roche Holding AG. These companies, like PharmaSGP Holding SE, specialize in the production and distribution of pharmaceutical products. As PharmaSGP Holding SE focuses on the niche market of over-the-counter (OTC) pharmaceuticals, it faces competition from other OTC brands such as Johnson & Johnson, Sanofi, and GlaxoSmithKline. In summary, PharmaSGP Holding SE competes against a diverse range of pharmaceutical companies, both in the OTC market and overall pharmaceutical industry.

PharmaSGP Holding SE is primarily active in the pharmaceutical and healthcare industry.

The business model of PharmaSGP Holding SE revolves around the development, production, and distribution of pharmaceutical and healthcare products. As a leading company in the consumer healthcare sector, PharmaSGP focuses on over-the-counter (OTC) medications, dietary supplements, and medical devices. By leveraging its strong network of partners and extensive marketing expertise, the company strives to provide accessible, high-quality healthcare solutions to its customers. PharmaSGP's product portfolio covers various therapeutic areas, including pain relief, cold and flu, and digestion. Through its commitment to innovation, quality, and customer satisfaction, PharmaSGP Holding SE continuously strives to improve health and well-being globally.

PharmaSGP Holding KGV yra 13,29.

PharmaSGP Holding KUV yra 2,26.

AlleAktien kokybės įvertis PharmaSGP Holding yra 6/10.

tikėtina PharmaSGP Holding pardavimai yra 111,66 mln. EUR.

tikėtina PharmaSGP Holding pelnas yra 18,95 mln. EUR.

PharmaSGP Holding SE is a leading provider of innovative products in the fields of health, beauty, and well-being. The company's business model is based on the development, manufacture, and marketing of high-quality dietary supplements, medical devices, and cosmetics. The products are organized into various segments, including naturopathy, sports nutrition, and anti-aging. In the field of naturopathy, the company offers a wide range of dietary supplements based on natural ingredients. These include products for stress, sleep disorders, or gastrointestinal problems. The products are developed in close collaboration with experts in medicine and naturopathy and meet the highest quality standards. In the field of sports nutrition, the company offers products specifically tailored to the needs of athletes. These contain high-quality, performance-enhancing ingredients such as amino acids, proteins, or carbohydrates. The range includes products for various applications, such as endurance or strength athletes. In the field of anti-aging, the company offers various products aimed at slowing down biological aging and improving skin structure. These include creams, serums, and capsules with antioxidant ingredients such as vitamin C or OPC. Products for improving hair and nails are also part of the range. In addition, PharmaSGP Holding SE is also active in the field of medical devices. This includes products for pain relief, regulation of blood sugar levels, or support of the immune system. The high quality of the products is also a focus in this area. The products are distributed under various brands such as Biotin, IronMaxx, or Biolectra and are available online as well as in pharmacies and drugstores. The marketing is done through both own distribution channels and partnerships. In addition to selling products, PharmaSGP Holding SE also focuses on the development of new technologies and products. This includes the development of apps and digital health solutions. Overall, the business model of PharmaSGP Holding SE is based on the development and marketing of high-quality products with a focus on naturopathy, sports nutrition, and anti-aging. The company relies on close collaboration with experts, highest quality standards, and innovative technologies.

PharmaSGP Holding moka dividendą 0,45 EUR, kuris yra paskirstytas per išmokas per metus.

Dividenda šiuo metu negali būti apskaičiuota PharmaSGP Holding arba įmonė dividendų nemoka.

PharmaSGP Holding ISIN yra DE000A2P4LJ5.

PharmaSGP Holding WKN yra A2P4LJ.

PharmaSGP Holding akcijų simbolis yra PSG.DE.

Per paskutinius 12 mėnesių PharmaSGP Holding išmokėjo dividendą, kurios dydis siekė 0,49 EUR . Tai atitinka maždaug 2,33 % dividendų grąžą. Artimiausiems 12 mėnesiams PharmaSGP Holding tikėtina išmokės dividendus, kurie sudarys 0,59 EUR.

PharmaSGP Holding šiuo metu yra 2,33 % dydžio dividendų grąža.

PharmaSGP Holding moka dividendus kas ketvirtį. Jie išmokami mėnesiais.

PharmaSGP Holding per paskutiniuosius 0 metus kiekvienais metais mokėjo dividendus.

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 0,59 EUR. Tai atitinka 2,83 % dividendų grąžos procentą.

PharmaSGP Holding priskiriamas sektoriui "Sveikata".

Norėdamas gauti paskutinį PharmaSGP Holding dividendą nuo 2024-07-01, kurio dydis yra 1,36 EUR, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2024-06-27.

Paskutinės dividendų išmokėjimas įvyko 2024-07-01.

2023 metais PharmaSGP Holding išmokėjo 0,45 EUR dividendų.

PharmaSGP Holding dividendai yra mokami EUR.